Floatz logo

Rimonabant

Coronary Atherosclerosis

SanofiSmall moleculePhase 3Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Coronary Atherosclerosis cohort.

Asset / SponsorPhaseRating
Rosuvastatin
Ukrainian Medical Stomatological Academy
Phase 4BB
Bisoprolol Fumarate
Ukrainian Medical Stomatological Academy
Phase 4BB
Isosorbide Dinitrate
Ukrainian Medical Stomatological Academy
Phase 4BB
Aspirin
Ukrainian Medical Stomatological Academy
Phase 4BB
Pioglitazone
Ukrainian Medical Stomatological Academy
Phase 4BB
Ezetimibe
Samsung Medical Center
Phase 4BB
Corpril
Ukrainian Medical Stomatological Academy
Phase 4BB
Edoxaban
Asan Medical Center
UnknownD

Same molecule, other indications

Rimonabant is also rated in:

obesity disorderDormant
CCC
Indicative · Phase 4
51 / 100
View asset →
inherited lipid metabolism disorderDormant
CCC
Indicative · Phase 3
50 / 100
View asset →
type 2 diabetes mellitusDormant
CCC
Indicative · Phase 3
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →